[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION 

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) 

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-38276

Apellis Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

100 Fifth Avenue

Waltham, MA 02451

(617) 977-5700

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.0001 par value per share

(Title of each class of securities covered by this Form)

None 

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)		☒
Rule 12g-4(a)(2)		☐
Rule 12h-3(b)(1)(i)		☒
Rule 12h-3(b)(1)(ii)		☐
Rule 15d-6		☐
Rule 15d-22(b)		☐

Approximate number of holders of record as of the certification or notice date: One (1)

Pursuant to the requirements of the Securities Exchange Act of 1934, Apellis Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: May 26, 2026	Apellis Pharmaceuticals, Inc.
	By:	/s/ Wendell Taylor
	Name:	Wendell Taylor
	Title:	Secretary